ADC Therapeutics Announces New Employee Inducement Grant

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) granted an inducement equity award of 17,000 options to a new employee on April 1, 2026. The award was approved by the Compensation Committee under the company's Inducement Plan and relies on the NYSE employment inducement exemption Rule 303A.08.

The options vest 25% after one year and then 1/48th monthly, fully vesting after four years, subject to continued employment.

News Market Reaction – ADCT

-0.53%

-0.53% Session close to close

In the Apr 2 session, ADCT declined 0.53%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a standard employee inducement grant for 17,000 options with four-year ves...

Analysis

This announcement details a standard employee inducement grant for 17,000 options with four-year vesting, using the NYSE employment inducement exemption under Rule 303A.08. It follows earlier 2026 grants under the same plan and sits against a backdrop of broader capital structure moves, including HCR warrants for 9,834,776 shares and an effective resale shelf permitting potential proceeds up to $37.5 million on cash exercise. Investors may watch overall equity issuance and warrant activity alongside upcoming LOTIS trial milestones.

Key Figures

Inducement options: 17,000 shares Initial vesting: 25% Ongoing vesting rate: 1/48th monthly +2 more

5 metrics

Inducement options 17,000 shares Options granted to one new employee on Apr 1, 2026

Initial vesting 25% Vests on first anniversary of grant date

Ongoing vesting rate 1/48th monthly Monthly vesting after year one until fully vested

Full vesting horizon 4 years Entire award vested by fourth anniversary, employment required

Grant date April 1, 2026 Date of employee inducement option grant

Historical Context

5 past events · Latest: Mar 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 10	Earnings and update	Positive	+13.5%	Q4 and 2025 results, cash runway and LOTIS trial timing updates.
Mar 03	Earnings call notice	Neutral	-3.1%	Announcement of timing for Q4 and full-year 2025 results call.
Mar 02	Employee inducement grants	Neutral	-3.1%	Stock options for three new employees under inducement plan.
Feb 24	Investor conferences	Neutral	-0.5%	Participation in March healthcare investor conferences and webcasts.
Feb 23	Royalty deal amendment	Neutral	+7.6%	Amended HealthCare Royalty agreement with new warrants and terms.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news flow shows stronger moves on earnings/financing updates, while routine items like conferences and inducement grants saw mild reactions.

Recent Company History

Over the last months, ADCT highlighted earnings and financing progress, including Q4 and full-year 2025 results with improved losses and a cash runway into 2028 on Mar 10, 2026, which coincided with a 13.48% gain. An amended royalty financing on Feb 23, 2026 was followed by a 7.56% rise. By contrast, routine items such as investor conferences and prior inducement grants in late February and early March saw only small price moves, framing today’s 17,000-share inducement grant as part of normal HR-related news flow.

Key Terms

antibody drug conjugates, options, employment inducement exemption

3 terms

antibody drug conjugates medical

"leader and pioneer in the field of antibody drug conjugates (ADCs)"

Antibody drug conjugates are targeted medicines that combine an antibody, which seeks out specific markers on diseased cells, with a powerful drug that is released only when the antibody binds its target. Think of it as a guided missile that delivers a toxic payload directly to its target, reducing damage to healthy cells; investors watch them because successful ADCs can offer high-value, niche treatments and drive strong revenue and patent-based protection for developers.

options financial

"made a grant of options to purchase an aggregate of 17,000"

Options are contracts that give investors the right to buy or sell an asset at a specific price within a certain time frame. They function like a reservation or a ticket that allows for potential profit or protection against price changes, making them useful tools for managing investment risks or speculating on market movements.

View in glossary

employment inducement exemption regulatory

"made in reliance on the employment inducement exemption under the NYSE's"

An employment inducement exemption is a regulatory allowance that lets a public company grant stock or option awards to a new hire without getting prior shareholder approval, provided the awards are given solely to attract or retain that employee and meet specific limits and rules. Investors care because these one-off grants increase the total number of shares available and can dilute existing ownership and earnings per share, much like adding more slices to an already shared pie.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on April 1, 2026 ("Grant").

The Grant was offered as material inducement to the employee's employment. The Grant was approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grant was made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08.

The Company is issuing this press release pursuant to Rule 303A.08. The Grant shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.

About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).

ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the timing of the PFS events and topline data release for LOTIS-5 and the results of the trial, the timing for the sBLA submission, acceptance and outcome of review of the sBLA submission, and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented by the Company on December 3, 2025, the timing, publication and outcome of the full LOTIS-7 trial, compendia inclusion and regulatory strategy and the commercial opportunity; expected cash runway at least to 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's clinical trials; the timing, publication and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including HealthCare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness, the impact on our future revenue streams, and the significant cash required to service such indebtedness; the impact, if any, from the amendment to the agreement with HealthCare Royalty Management and our strategic alternatives; the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions, trade barriers and most favored nation drug pricing and the potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-announces-new-employee-inducement-grant-302729093.html

SOURCE ADC Therapeutics SA

FAQ

What did ADC Therapeutics (ADCT) announce on April 1, 2026 about employee equity?

ADC Therapeutics granted an inducement award of 17,000 options to a new employee on April 1, 2026. According to the company, the grant was approved by the Compensation Committee under the Inducement Plan and relies on the NYSE Rule 303A.08 exemption.

How do the 17,000 options granted by ADCT vest and when do they fully vest?

The options vest 25% after one year and monthly thereafter, fully vesting in four years. According to the company, vesting is 25% on the first anniversary and 1/48th monthly thereafter, subject to continued employment.

Why did ADC Therapeutics (ADCT) use an inducement grant for the new employee?

The company offered the grant as a material inducement to secure the new hire and incentivize performance. According to the company, the award aims to motivate and reward the recipient to contribute significantly to company success.

Under what NYSE rule did ADC Therapeutics (ADCT) rely to issue the inducement award?

ADCT relied on the NYSE employment inducement exemption Rule 303A.08 to issue the options to a new hire. According to the company, the grant was made pursuant to that exemption and disclosed under Rule 303A.08.

Was the inducement award to the new ADCT employee approved by the board or a committee?

The award was approved by the Compensation Committee of the board rather than the full board. According to the company, the Compensation Committee approved the grant under the Inducement Plan to motivate the recipient.